<DOC>
	<DOCNO>NCT02968641</DOCNO>
	<brief_summary>A Phase 2b , Open-Label , Randomized Study Safety , Tolerability , Pharmacodynamic Activity Lonafarnib With Without Ritonavir Patients Chronically Infected Hepatitis Delta Virus</brief_summary>
	<brief_title>A Study Lonafarnib With Without Ritonavir Patients With HDV</brief_title>
	<detailed_description>This Phase 2b , randomize , open-label study ass safety , tolerability , pharmacodynamics ( PD ) /efficacy 48 week lonafarnib ( LNF ) ritonavir ( RTV ) combination therapy vs. LNF monotherapy patient chronically infect Hepatitis Delta Virus ( CHD ) . Sixty patient enrol single study site . Eligible patient CHD infection ( ≥ 6 month ) confirm positive HDV antibody ( Ab ) test HDV RNA ≥ 3 lg IU/mL quantitative polymerase chain reaction ( qPCR ) study entry .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Willing able comply study procedure provide write consent 2 . 18 65 year old 3 . Body mass index ( BMI ) ≥ 18 kg/m2 weigh ≥ 45 kg 4 . CHD infection least 6 month ' duration document positive HDV antibody ( Ab ) test HDV RNA ≥ 3 log10/mL qPCR study entry 5 . Serum ALT &gt; upper limit normal range ( ULN ) &lt; 10 × ULN 6 . Liver biopsy within 12 month Day 1 demonstrate evidence chronic hepatitis . If liver biopsy available , patient must willing consent contraindication liver biopsy 7 . ECGs demonstrate acute ischemia clinically significant abnormality QT interval correct heart rate ( QTcF ) &lt; 450 m male patient &lt; 460 ms female patient 8 . Dilated retinal examination ≤ 1 year screening : For patient diabetes , hypertension , risk factor retinal disease , perform licensed ocular specialist ; patient , normal retinal examination assess investigator license ocular specialist 9 . Female patient childbearing potential male patient partner childbearing potential must agree use adequate method contraception study 90 day last dose study drug . Female patient childbearing potential except patient surgically sterile , medically document ovarian failure , least 1 year postmenopausal . For female : 2 follow contraceptive method , least 1 barrier method : Hormonal contraceptive ≥ 3 month screen Intrauterine device ( IUD ) place ≥ 3 month screen Doublebarrier method ( use condom [ male partner ] either diaphragm spermicide cervical cap spermicide ) screen Surgical sterilization partner ( vasectomy ≥ 1 month screening ) For male : Surgical sterilization ( vasectomy ≥ 1 month screening ) Both follow contraceptive method screen : Consistently correctly use condom Partner must agree use hormonal contraceptive nonhormonal barrier method ( IUD diaphragm spermicide cervical cap spermicide ) General Exclusions 1 . Participation clinical trial , use , investigational agent within 30 day screen 2 . Previous use LNF . 3 . Female patient pregnant breastfeeding . Male patient must confirm female sexual partner pregnant . Female patient must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin [ hCG ] ) within 24 hour prior start investigational agent ) . Exclusions Based Disease 4 . Current previous history decompensated liver disease ( ChildPugh Class B C ) 5 . Coinfected human immunodeficiency virus ( HIV ) hepatitis C virus ( HCV ) . 6 . Positive result HIV HCV Ab screen . Patients positive HCV Ab screening allow complete curative antiviral regimen document undetectable HCV RNA least 3 month screen screening . 7 . Past history current evidence decompensated liver disease , define follow screening : Bilirubin level ≥ 2.5 mg/dL unless due Gilbert 's disease Serum albumin level &lt; 3.0 g/dL International normalized ratio ( INR ) ≥ 1.5 8 . Evidence significant portal hypertension hepatic venous pressure gradient ( HVPG ) ≥ 10 mmHg ; current presence history esophageal abdominal varix , variceal bleeding , splenomegaly &gt; 12 cm length image 9 . Current evidence history ascites require diuretic paracentesis , hepatic encephalopathy 10 . Current evidence history hepatic encephalopathy 11 . Any following abnormal laboratory test result screen : Platelet count &lt; 90,000 cells/mm3 White blood cell ( WBC ) count &lt; 3,000 cells/mm3 Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 Hemoglobin &lt; 11 g/dL woman &lt; 12 g/dL men Serum creatinine concentration ≥ 1.5 × ULN Confirmed creatinine clearance ( CrCl ) &lt; 50 mL/min CockroftGault estimate glomerular filtration rate ( eGFR ) &gt; 80 mL/min screening , base CockcroftGault equation Alphafetoprotein ≥ 100 ng/mL 12 . Evidence another form viral hepatitis another form liver disease ( eg , autoimmune liver disease , primary biliary cirrhosis , primary sclerosing cholangitis , Wilson 's disease , alcoholic liver disease , nonalcoholic steatohepatitis , hemochromatosis , alpha1antitrypsin deficiency ) 13 . History hepatocellular carcinoma 14 . Patients follow : Current eat disorder alcohol abuse Excessive alcohol intake , define follow : &gt; 20 g/day female ( 1.5 standard alcohol drink ) &gt; 30 g/day male ( 2.0 standard alcohol drink ) . A standard drink contain 14 g alcohol : 360 mL beer , 150 mL wine , 45 mL spirit In opinion investigator , alcohol use pattern interfere study conduct Drug abuse within previous 6 month screen , exception cannabinoids derivatives 15 . Prior history current evidence following : Immunologically mediate disease ( eg , rheumatoid arthritis , inflammatory bowel disease , severe psoriasis , systemic lupus erythematosus ) require intermittent nonsteroidal antiinflammatory medication management require use systemic corticosteroid 6 month screen ( inhaled asthma medication allow ) Retinal disorder clinically relevant ophthalmic disorder Any malignancy within 5 year screen . Exceptions superficial dermatologic malignancy ( eg , squamous cell basal cell skin cancer treat curative intent ) , successfully treat insitu carcinoma cervix . Cardiomyopathy significant ischemic cardiac cerebrovascular disease ( include history angina , myocardial infarction , interventional procedure coronary artery disease ) Chronic pulmonary disease ( eg , chronic obstructive pulmonary disease ) associate functional impairment Pancreatitis Severe uncontrolled psychiatric disorder ( eg , depression , manic condition , psychosis , acute and/or chronic cognitive dysfunction , suicidal behavior , relapse substance abuse ) Bone marrow solid organ transplantation 16 . Other significant medical condition may require intervention study . Patients serious condition , opinion investigator , would preclude evaluation response make unlikely contemplated course therapy followup could complete . Patients participation study would increase risk . Exclusions Based Concurrent Medication Use 17 . Any prescription herbal product approve investigator 18 . Therapy immunomodulatory agent , IFNalfa ( IFN alfa2a IFN alfa2b , pegylated IFN alfa2a alfa2b ) , cytotoxic agent , systemic corticosteroid within 12 month screen study 19 . Use heparin warfarin study 20 . Systemic antibiotic , antifungal , antiviral treatment active infection HBV within 14 day study randomization study 21 . Longterm treatment ( &gt; 2 week ) study agent high risk nephrotoxicity hepatotoxicity unless approve medical monitor 22 . Receipt systemic immunosuppressive therapy within 3 month screen study 23 . History evidence intolerance hypersensitivity LNF , RTV , substances part study drug 24 . Concomitant use following : Medications food know moderate strong inducer inhibitor CYP3A4 Drugs know prolong PR QT interval unless otherwise describe protocol Statins , due inhibition mevalonate synthesis , reduce protein prenylation 25 . Concomitant use medication contraindicate prescribe information RTV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>